They show that oncolytic measles virus encoding s-NAP (MV-s-NAP) exhibits significant anti-tumor effects, highlighting a promising immunovirotherapy approach for recurrent or disseminated synovial sarcoma. Here, CTNNBL1 is linked to synovial sarcoma.